United States-based Eli Lilly and Innovent Biologics, a domestic biopharmaceutical company, jointly announced that Sintilimab injection, a PD-1 inhibitor, has been approved to treat gastric or gastroesophageal junction adenocarcinoma by China's National Medical Products Administration.
总部位于美国的礼来公司和国内生物制药公司Innovent Biologics联合宣布，PD-1抑制剂辛蒂利单抗注射液已被中国国家药品监督管理局批准用于治疗胃或胃食管交界腺癌。
According to the approval released on Friday, the injected drug shall be used in combination with other medicines for first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
根据周五发布的批准，注射药物应与其他药物联合使用，用于不可切除、局部晚期、复发或转移性胃或胃食管交界腺癌的一线治疗。
========================================================
部分内容来自网络，如有版权问题请与我们联系
未经许可，严禁转发。QQ交流群：688169419
========================================================